Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Researchers in the hunt for ‘holy grail’ of pain relief

October 19, 2018

A new generation of opioids with fewer side effects is being explored by an Australian and Chinese research team.

Emeritus Professor Maree Smith of the School of Biomedical Sciences at the University of Queensland will present research on oliceridine, a novel opioid being developed internationally, as well as results from her team’s CYX-6 research project at a meeting of specialist pain medicine physicians tomorrow. (SATURDAY)

Local and international specialist pain medicine physicians are attending the Australian and New Zealand College of Anaesthetists’ Faculty of Pain Medicine (FPM) meeting from October 19-21 in Cairns.

Professor Smith, Executive Director of the Centre for Integrated Preclinical Drug Development (CIPDD), stressed that while the research project was still in its early stages laboratory tests were promising as they had found that a newly discovered compound, CYX-6, spared laboratory rats from some of the more common side effects of opioid use – respiratory depression and constipation.

Strong opioids that are used for pain relief such as morphine and fentanyl can have other serious and sometimes fatal side effects such as drowsiness, respiratory depression and addiction depending on their dose and application.

“We’ve seen with the opioid crisis in the US there are many people who are dying as a result of taking either too many opioids or doses that are too high because they stop breathing,” Professor Smith explained.

“So being able to develop an opioid with a reduced propensity for breathing difficulties would be a very positive step.”

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

Professor Smith’s laboratory is exploring the new opioid as part of a collaboration with Chinese researcher/medicinal chemist, Professor Tingyou Li from Nanjing Medical University in Nanjing, China.

Professor Smith described the search for the next generation of opioid analgesics as “the holy grail of opioid development”.

“We and other international laboratories are focused on discovery of new opioid alternatives with fewer side effects. It is a hot topic in the research world at present.”

Dr Meredith Craigie, the Dean of FPM, said research into opioid alternatives such as that being carried out by Professor Smith and her team were a significant step in the development of potential new treatments for pain management.

About FPM

The Faculty of Pain Medicine is a world-leading professional organisation for pain specialists that sets standards in pain medicine and is responsible for education and training in the discipline in Australia and New Zealand. Pain medicine is multidisciplinary, recognising that the management of severe pain requires the skills or more than one area of medicine.

Chronic pain affects about one in five people in Australia and New Zealand. Specialists also manage acute pain (post-operative, post-trauma, acute episodes of pain in medical conditions) and cancer pain.

ends

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.